Characterization of Domiphen Bromide as a New Fast-Acting Antiplasmodial Agent Inhibiting the Apicoplastidic Methyl Erythritol Phosphate Pathway.

Plasmodium falciparum antibiotics antimalarial drugs domiphen bromide malaria methyl erythritol phosphate pathway

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
22 Jun 2022
Historique:
received: 16 05 2022
revised: 16 06 2022
accepted: 18 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

The evolution of resistance by the malaria parasite to artemisinin, the key component of the combination therapy strategies that are at the core of current antimalarial treatments, calls for the urgent identification of new fast-acting antimalarials. The apicoplast organelle is a preferred target of antimalarial drugs because it contains biochemical processes absent from the human host. Fosmidomycin is the only drug in clinical trials targeting the apicoplast, where it inhibits the methyl erythritol phosphate (MEP) pathway. Here, we characterized the antiplasmodial activity of domiphen bromide (DB), another MEP pathway inhibitor with a rapid mode of action that arrests the in vitro growth of

Identifiants

pubmed: 35890216
pii: pharmaceutics14071320
doi: 10.3390/pharmaceutics14071320
pmc: PMC9319574
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Science, Innovation and Universities, Spain
ID : RTI2018-094579-B-I00
Organisme : Government of Catalonia
ID : 2017-SGR-908

Références

J Control Release. 2014 Mar 10;177:84-95
pubmed: 24412735
Nat Commun. 2021 Jul 27;12(1):4563
pubmed: 34315897
Nature. 1997 Nov 27;390(6658):407-9
pubmed: 9389481
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S54-S64
pubmed: 28040698
J Control Release. 2021 Mar 10;331:364-375
pubmed: 33497747
J Biol Chem. 2004 Dec 10;279(50):51749-59
pubmed: 15452112
Nature. 2007 Mar 1;446(7131):88-91
pubmed: 17330044
Elife. 2020 May 12;9:
pubmed: 32394893
Biochim Biophys Acta. 1970 Apr 22;206(1):143-51
pubmed: 5462423
Science. 1999 Sep 3;285(5433):1573-6
pubmed: 10477522
Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):363-5
pubmed: 9231219
Sci Rep. 2016 Dec 07;6:38615
pubmed: 27924931
J Mol Recognit. 2011 Jan-Feb;24(1):71-80
pubmed: 20213667
J Control Release. 2011 Apr 30;151(2):202-11
pubmed: 21223986
Trends Parasitol. 2008 Jun;24(6):279-84
pubmed: 18450512
Future Microbiol. 2015;10(8):1375-90
pubmed: 26228767
mBio. 2021 Jun 29;12(3):e0076021
pubmed: 34182772
J Biol Chem. 2003 May 16;278(20):18401-7
pubmed: 12621040
Eukaryot Cell. 2015 Feb;14(2):128-39
pubmed: 25446055
Science. 1972 Jul 14;177(4044):175-7
pubmed: 4339353
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
Clin Infect Dis. 2018 Jun 1;66(12):1823-1830
pubmed: 29293893
J Control Release. 2015 Jul 28;210:217-29
pubmed: 26008752
Front Microbiol. 2016 Sep 13;7:1421
pubmed: 27679614
PLoS Biol. 2019 Jul 18;17(7):e3000376
pubmed: 31318858
Biochem J. 1999 Aug 1;341 ( Pt 3):629-37
pubmed: 10417326
Curr Pharm Des. 2004;10(19):2391-400
pubmed: 15279616
PLoS Biol. 2011 Aug;9(8):e1001138
pubmed: 21912516
Eur J Pharmacol. 2014 Aug 15;737:202-9
pubmed: 24846011
J Pharm Biomed Anal. 2018 Sep 10;159:224-228
pubmed: 29990889
Eur J Pharmacol. 2012 Nov 5;694(1-3):45-52
pubmed: 22975264
Annu Rev Biochem. 1976;45:113-42
pubmed: 9026
J Pharm Biomed Anal. 2022 Jan 20;208:114450
pubmed: 34798391
Trends Parasitol. 2021 Jan;37(1):15-24
pubmed: 33060063
ACS Infect Dis. 2018 Apr 13;4(4):549-559
pubmed: 29072835
Biochemistry. 2003 Feb 4;42(4):1140-9
pubmed: 12549936
J Parasitol. 1979 Jun;65(3):418-20
pubmed: 383936
Science. 2008 Apr 18;320(5874):330-4
pubmed: 18420924
Talanta. 2021 Feb 1;223(Pt 2):121740
pubmed: 33298266
Pharmaceutics. 2019 Jul 16;11(7):
pubmed: 31315185
Antimicrob Agents Chemother. 2015 Jan;59(1):356-64
pubmed: 25367906
Eukaryot Cell. 2014 Nov;13(11):1348-59
pubmed: 25217461
Antimicrob Agents Chemother. 2007 Oct;51(10):3485-90
pubmed: 17698630
J Biol Chem. 2009 Apr 10;284(15):9974-85
pubmed: 19203994
Eukaryot Cell. 2013 Feb;12(2):215-23
pubmed: 23223036
Biochem Soc Trans. 2000 Dec;28(6):785-9
pubmed: 11171208
Gene. 2018 Oct 30;675:240-253
pubmed: 29958953
Int J Clin Pharmacol Res. 1983;3(5):357-61
pubmed: 6381338
Life Sci. 2016 Aug 1;158:104-10
pubmed: 27381078
PLoS One. 2013 Jun 17;8(6):e62906
pubmed: 23798988
Parasit Vectors. 2017 Oct 10;10(1):461
pubmed: 29017543
Biomaterials. 2017 Nov;145:178-191
pubmed: 28869864
Biomaterials. 2014 Sep;35(27):7940-50
pubmed: 24930847
Molecules. 2019 Oct 07;24(19):
pubmed: 31591293
Curr Clin Microbiol Rep. 2014 Dec 1;1(3-4):37-50
pubmed: 25893156
Nat Rev Microbiol. 2009 Dec;7(12):864-74
pubmed: 19881520
Drug Resist Updat. 2001 Jun;4(3):145-51
pubmed: 11768328
ChemMedChem. 2022 Mar 4;17(5):e202100679
pubmed: 34918860

Auteurs

Arnau Biosca (A)

Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, 08028 Barcelona, Spain.
Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.

Miriam Ramírez (M)

Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.

Alex Gomez-Gomez (A)

Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Doctor Aiguader 88, 08003 Barcelona, Spain.
Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain.

Aritz Lafuente (A)

Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, 08028 Barcelona, Spain.
Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.

Valentín Iglesias (V)

Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, 08028 Barcelona, Spain.
Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.
Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

Oscar J Pozo (OJ)

Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Doctor Aiguader 88, 08003 Barcelona, Spain.
Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain.

Santiago Imperial (S)

Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.
Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain.

Xavier Fernàndez-Busquets (X)

Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, 08028 Barcelona, Spain.
Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.

Classifications MeSH